BioSpace News Archive

Elidah Inc., a growing medical solutions company that focuses on delivering FDA-cleared, clinically-proven treatment devices for difficult-to-treat female health urinary conditions announced that it has signed a national agreement with VGM & Associates.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Athena Countouriotis, M.D., as the chairperson of the board of directors.

Axial Therapeutics Inc. today announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall webconference on Wednesday, September 21, 2022.

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Triphosphate, a modified nucleoside-triphosphate essential for mRNA manufacturing.

Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today provided a business update and reported financial results for the fiscal first quarter ended July 31, 2022.

Delix Therapeutics (the “Company”), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, has been named to Nature Biotechnology’s list of leading spinouts of 2021.

Promontory Therapeutics Inc. today announced the appointments of Helene Shea , PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC), and Kate Hogg Call as Vice President of Clinical Operations.

Smart Immune SAS announced that it has appointed Dr Frederic Lehmann as Chief Medical Officer and Dr Pierre Heimendinger as Chief Technical Officer.

ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced an update on its previously announced restructuring efforts.

KBio, a leading developer of new biological treatments derived from a plant-based production system, today announced that it has entered into a strategic partnership agreement with ZabBio to develop a new generation of mAbs, as well as advance the development of select assets within ZabBio’s current mAb pipeline.